Visit KQAK 105.7
Visit The Peak 104.1
Visit 95.7 The Ranch
Visit 92.5 The Ticket
Visit KBNW 104.5AM AND 1340AM
Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alkermes plc

News headline image
Alkermes to Report Third Quarter Financial Results on November 3, 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes plc Reports Second Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Report Second Quarter Financial Results on July 28, 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes plc Reports First Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Report First Quarter Financial Results on May 5, 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes plc Announces CEO Succession Plan
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
From Alkermes plc
Via Business Wire
Tickers ALKS AVDL
News headline image
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
From Alkermes plc
Via Business Wire
Tickers ALKS
News headline image
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Alkermes plc
Via Business Wire
Tickers ALKS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.